HTN in Young Adulthood Linked to CVD Later in Life
WEDNESDAY, Nov. 7, 2018 -- High blood pressure (BP) in early adulthood is associated with an increased risk for cardiovascular disease (CVD) later in life, according to two studies published in the Nov. 6 issue of the Journal of the American Medical Association.
Yuichiro Yano, M.D., Ph.D., from Duke University in Durham, North Carolina, and colleagues examined the risk for CVD events associated with hypertension in young adults aged 18 to 30 years from four U.S. field centers. Data were included for 4,851 adults. The researchers identified 228 incident CVD events during a median follow-up of 18.8 years. The CVD incidence rates were 1.37, 2.74, 3.15, and 8.04 for normal BP, elevated BP, stage 1 hypertension, and stage 2 hypertension, respectively. After multivariable adjustment, the hazard ratios (HRs) for CVD events were 1.67, 1.75, and 3.49 for elevated BP, stage 1 hypertension, and stage 2 hypertension, respectively, compared with normal BP.
Joung Sik Son, M.D., from the Seoul National University Hospital in South Korea, and colleagues categorized 2,488,101 Korean adults aged 20 through 39 years according to BP readings and examined the correlation between categories and risk for CVD later in life. During a median follow-up of 10 years, the researchers observed 44,813 CVD events. Compared with those with normal BP, increased risks for CVD, coronary heart disease (CHD), and stroke were seen for men with baseline stage 1 hypertension (adjusted HRs, 1.25, 1.23, and 1.30, respectively) and women with stage 1 hypertension (adjusted HRs, 1.27, 1.16, and 1.37, respectively). Results were consistent for stage 2 hypertension.
"Overall, these data emphasize that primary prevention of higher blood pressure levels must begin in childhood," writes the author of an accompanying editorial.
One author from the Yano study disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text - Yano (subscription or payment may be required)
Abstract/Full Text - Sik Son (subscription or payment may be required)
Editorial - Vasan (subscription or payment may be required)
Editorial - Fisher and Curfman (subscription or payment may be required)
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.